EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

7:00am - 8:00am 60 mins
Continental Breakfast
7:00am - 6:00pm 660 mins
Registration Open
8:00am - 8:55am 55 mins
Investing in next gen immunotherapies: Moving the checkpoint inhibitors to the next level
  • Moderator Jeffrey Bockman - Executive VP, Oncology Practice Head, Defined Health, a Cello Health Business
  • Panelist Bibhash Mukhopadhyay - Principal, New Enterprise Associates
  • Panelist Thomas J. Schuetz - Co-Founder and CEO, Compass Therapeutics

While the frenzy around funding immuno-oncology agents has started to settle down from its peak in 2015–2016, the question remains open as to which if any of these many “first generation” programs for solid tumors looking to enhance the activity of checkpoint inhibitors and/or attempting to render colder tumors hotter will actually provide the next big shift in clinical management. Data to date has been disappointing to mixed at best. When looking to the future of immunotherapy, one wonders if there will be for the foreseeable future only more incremental advances. But where are the next big paradigm shifts going to be, where is the next great target that will supersize foundational checkpoint therapy? This panel will probe these issues especially as they relate to creating value not only for investors and potential partners but most critically for patients.

8:00am - 8:55am 55 mins
NASH MOAs: A highly competitive playing field
  • Moderator Yasmeen Rahimi - Managing Director, Senior Research Analyst, Roth

With many new drugs and molecular targets in development and no FDA-approved therapeutics to treat NASH, the competitive environment is heating up. Although there is increased interest in NASH, the complexity as a multi-factorial disease and the long time frame for drug development is not without challenges. What are the key pros and cons of the multiple key mechanisms of action and will there be an approval in 2019?

8:00am - 6:00pm 600 mins
One-to-one meetings
8:30am - 12:00pm 210 mins
Company Presentations
12:00pm - 1:45pm 105 mins
Lunch Plenary: The booming biotech ecosystem: The playing field has evolved, and the bases are loaded. How long will the streak continue?
  • Moderator Michelle Keefe - President, Commercial Solutions, Syneos Health
  • Panelist Camille Samuels - Partner, Venrock
1:45pm - 5:30pm 225 mins
Company Presentations
4:00pm - 4:55pm 55 mins
An H&Q reunion: A retrospective look at the biotech sector with former analysts
  • Moderator Dennis Purcell - Founder and Senior Advisor, Aisling Capital
  • Panelist Kristin Carey - Managing Director, Cain Brothers
  • Panelist Meg Malloy, Music Therapy
  • Panelist Rich van den Broek - Partner, HSMR Advisors
  • Panelist Alex Zisson - Managing Director, H.I.G. Capital
Showing of Streams